Apheresis technologies for prevention and regression of atherosclerosis: Clinical results

ASAIO Journal

Volumn 45, Issue 5, 1999, Pages 403-407

  Bambauer, Rolf ^a   Schneidewind, Jana Maria ^a   Latza, Reinhard ^a  

^a Institute for Blood Purification   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYSULFONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADSORPTION; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEVICE; DIET; DRUG USE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HOLLOW FIBER MEMBRANE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTENSION; INSTRUMENTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; SAFETY; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CHILD; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 0033200921     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Castelli WP, Gerrison RJ, Wilson WF, et al: Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 256: 2835-2838, 1986.
2. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continued and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA, 256: 2823-2828, 1986.
3. Assmann AG, Schulte H (eds): Procam-trial (The Muenster Cardiovascular Trial). Panscientia Verlag, 1986.
4. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364, 1984.
5. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment. Changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245, 1987.
6. Hjermann I, Holme I, Velve Byre K, Leren P: Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial in healthy men. Lancet 2: 1303-1310, 1981.
7. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 264: 3013-1017, 1990.
8. Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:12889-12898, 1990.
9. Ornish D, Brown SE, Scherwitz LW, et al: Can lifestyle changes reverse coronary heart disease? The Lifestyles Heart Trial. Lancet 336: 129-133, 1990.